Sat­suma's nasal mi­graine can­di­date re­ject­ed by FDA over CMC is­sues 

Sat­suma Phar­ma­ceu­ti­cals was hand­ed a com­plete re­sponse let­ter for its nasal mi­graine drug af­ter the agency found is­sues with the prod­uct’s chem­istry, man­u­fac­tur­ing and con­trols.

No is­sues were found re­lat­ed to the drug’s safe­ty, dubbed STS101, and no ad­di­tion­al clin­i­cal tri­als are need­ed, the com­pa­ny said Thurs­day. Sat­suma is in dis­cus­sions with the FDA and is con­sid­er­ing reap­ply­ing for an­oth­er new drug ap­proval for STS101.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER